ASX-LISTED biotech company Actinogen Medical has reached a milestone in Alzheimer's disease (AD) research with the recruitment of the first patient in a Phase II clinical trial of its cortisol-blocking drug Xanamem.
The researchers plan to enrol 174 patients at 20 sites across Australia, the UK and USA, the largest study of its kind ever conducted by an Australian biotech company.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 May 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 May 17